A distinct bone phenotype in ADPKD patients with end-stage renal disease.

[en] Autosomal dominant polycystic kidney disease (ADPKD) is among the most common hereditary nephropathies. Low bone turnover osteopenia has been reported in mice with conditional deletion of the PKD1 and PKD2 genes in osteoblasts, and preliminary clinical data also suggest suppressed bone turnover in patients with ADPKD. The present study compared the bone phenotype between patients with end stage renal disease (ESRD) due to ADPKD and controls with ESRD due to other causes. Laboratory parameters of bone mineral metabolism (fibroblast growth factor 23 and sclerostin), bone turnover markers (bone alkaline phosphatase, tartrate-resistant acid phosphatase 5b) and bone mineral density (BMD, by dual energy x-ray absorptiometry, DXA) were assessed in 518 patients with ESRD, including 99 with ADPKD. Bone histomorphometry data were available in 71 patients, including 10 with ADPKD. Circulating levels of bone alkaline phosphatase were significantly lower in patients with ADPKD (17.4 vs 22.6 ng/mL), as were histomorphometric parameters of bone formation. Associations between ADPKD and parameters of bone formation persisted after adjustment for classical determinants including parathyroid hormone, age, and sex. BMD was higher in skeletal sites rich in cortical bone in patients with ADPKD compared to non-ADPKD patients (Z-score midshaft radius -0.04 vs -0.14; femoral neck -0.72 vs -1.02). Circulating sclerostin levels were significantly higher in ADPKD patients (2.20 vs 1.84 ng/L). In conclusion, patients with ESRD due to ADPKD present a distinct bone and mineral phenotype, characterized by suppressed bone turnover, better preserved cortical BMD, and high sclerostin levels.

Disciplines :

Urology & nephrology
Laboratory medicine & medical technology

Author, co-author :

Evenepoel, Pieter

Claes, Kathleen

Cavalier, Etienne ; Université de Liège - ULiège > Département de pharmacie > Chimie médicale

Meijers, Bjorn

Stenvinkel, Peter

Behets, Geert J.

Jankowska, Magdalena

D'Haese, Patrick

Bammens, Bert

Language :

English

Title :

A distinct bone phenotype in ADPKD patients with end-stage renal disease.

Publication date :

2019

Journal title :

Kidney International

ISSN :

0085-2538

eISSN :

1523-1755

Publisher :

Elsevier, United States - New York

Volume :

Issue :

Pages :

412-419

Peer reviewed :

Peer Reviewed verified by ORBi

Commentary :

Available on ORBi :

since 25 January 2019

Statistics

Number of views

56 (3 by ULiège)

Number of downloads

2 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Ong, A.C., Devuyst, O., Knebelmann, B., Walz, G., Autosomal dominant polycystic kidney disease: the changing face of clinical management. Lancet 385:9981 (2015), 1993–2002.
Torres, V.E., Harris, P.C., Pirson, Y., Autosomal dominant polycystic kidney disease. Lancet 369:9569 (2007), 1287–1301.
Peters, D.J.M., Sandkuijl, L.A., Genetic heterogeneity of polycystic kidney disease in Europe. Contrib Nephrol 97 (1992), 128–139.
Hughes, J., Ward, C.J., Peral, B., et al. The polycystic kidney disease 1 (PKD1) gene encodes a novel protein with multiple cell recognition domains. Nat Genet 10:2 (1995), 151–160.
Mochizuki, T., Wu, G., Hayashi, T., et al. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science 272:5266 (1996), 1339–1342.
Nguyen, A.M., Jacobs, C.R., Emerging role of primary cilia as mechanosensors in osteocytes. Bone 54:2 (2013), 196–204.
Yuan, X., Serra, R.A., Yang, S., Function and regulation of primary cilia and intraflagellar transport proteins in the skeleton. Ann N Y Acad Sci 1335 (2015), 78–99.
Yoder, B.K., Hou, X., Guay-Woodford, L.M., The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal cilia. J Am Soc Nephrol 13:10 (2002), 2508–2516.
Temiyasathit, S., Jacobs, C.R., Osteocyte primary cilium and its role in bone mechanotransduction. Ann N Y Acad Sci 1192 (2010), 422–428.
Xiao, Z., Quarles, L.D., Physiological mechanisms and therapeutic potential of bone mechanosensing. Rev Endocr Metab Disord 16:2 (2015), 115–129.
Xiao, Z., Dallas, M., Qiu, N., et al. Conditional deletion of Pkd1 in osteocytes disrupts skeletal mechanosensing in mice. FASEB J 25:7 (2011), 2418–2432.
Xiao, Z., Zhang, S., Mahlios, J., et al. Cilia-like structures and polycystin-1 in osteoblasts/osteocytes and associated abnormalities in skeletogenesis and Runx2 expression. J Biol Chem 281:41 (2006), 30884–30895.
Gitomer BY, Pereira RC, Malaczewski MR, et al. Identification of a bone defect in ADPKD. Oral abstract presented at Kidney Week of the American Nephrology Society, November 11–16, 2014; Philadelphia, PA.
Gitomer BY, Stoneback JW, Pereira RC, et al. Bone mineral density is reduced in patients with autosomal dominant polycystic kidney disease. Poster abstract presented at Kidney Week of the American Nephrology Society, November 15–20, 2016; Chicago, IL.
Moorhead, J.F., Tatler, G.L., Baillod, R.A., et al. Effects of age, sex, and polycystic disease on progressive bone disease of renal failure. Br Med J 4:5944 (1974), 557–560.
Torres, P.U., Bover, J., Mazzaferro, S., et al. When, how, and why a bone biopsy should be performed in patients with chronic kidney disease. Semin Nephrol 34:6 (2014), 612–625.
Frost, M.L., Compston, J.E., Goldsmith, D., et al. (18)F-fluoride positron emission tomography measurements of regional bone formation in hemodialysis patients with suspected adynamic bone disease. Calcif Tissue Int 93:5 (2013), 436–447.
De Rechter, S., Bacchetta, J., Godefroid, N., et al. Evidence for bone and mineral metabolism alterations in children with autosomal dominant polycystic kidney disease. J Clin Endocrinol Metab 102:11 (2017), 4210–4217.
Jankowska, M., Haarhaus, M., Qureshi, A.R., et al. Sclerostin horizontal line A debutant on the autosomal dominant polycystic kidney disease scene?. Kidney Int Rep 2:3 (2017), 481–485.
Gitomer BY, Wolf MS, Salusky IB, et al. Low serum levels of alkaline phosphatase are associated with greater total kidney volume in patients with early autosomal dominant polycystic kidney disease. Poster abstract presented at Kidney Week of the American Nephrology Society, November 15–20, 2016; Chicago, IL.
Baron, R., Kneissel, M., WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med 19:2 (2013), 179–192.
Spatz, J.M., Wein, M.N., Gooi, J.H., et al. The Wnt inhibitor sclerostin is up-regulated by mechanical unloading in osteocytes in vitro. J Biol Chem 290:27 (2015), 16744–16758.
Corbit, K.C., Shyer, A.E., Dowdle, W.E., et al. Kif3a constrains beta-catenin-dependent Wnt signalling through dual ciliary and non-ciliary mechanisms. Nat Cell Biol 10:1 (2008), 70–76.
Raptis, V., Bakogiannis, C., Loutradis, C., et al. Levels of endocan, angiopoietin-2, and hypoxia-inducible factor-1a in patients with autosomal dominant polycystic kidney disease and different levels of renal function. Am J Nephrol 47:4 (2018), 231–238.
Chen, D., Li, Y., Zhou, Z., et al. HIF-1alpha inhibits Wnt signaling pathway by activating Sost expression in osteoblasts. PLoS One, 8(6), 2013, e65940.
Cejka, D., Herberth, J., Branscum, A.J., et al. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol 6:4 (2011), 877–882.
Drechsler, C., Evenepoel, P., Vervloet, M.G., et al. High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant 30:2 (2014), 288–293.
Viaene, L., Behets, G.J., Claes, K., et al. Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis?. Nephrol Dial Transplant 28:12 (2013), 3024–3030.
Ryan, Z.C., Ketha, H., McNulty, M.S., et al. Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium. Proc Natl Acad Sci U S A 110:15 (2013), 6199–6204.
Bala, Y., Farlay, D., Boivin, G., Bone mineralization: from tissue to crystal in normal and pathological contexts. Osteoporos Int 24:8 (2013), 2153–2166.
Naylor, K.L., Jamal, S.A., Zou, G., et al. Fracture incidence in adult kidney transplant recipients. Transplantation 100:1 (2016), 167–175.
Gitomer BY, Dalrymple LS, You Z, et al. Fracture rates and post-discharge outcomes among patients undergoing hemodialysis across etiologies of kidney diseases. Poster abstract presented at Kidney Week of the American Nephrology Society, October 31–November 5, 2017; New Orleans, LA.
Pavik, I., Jaeger, P., Ebner, L., et al. Soluble Klotho and autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 7:2 (2012), 248–257.
Bouillon, R., Van Herck, E., Jans, I., et al. Two direct (nonchromatographic) assays for 25-hydroxyvitamin D. Clin Chem 30:11 (1984), 1731–1736.
Bouillon, R., De Moor, P., Baggiolini, E.G., Uskokovic, M.R., A radioimmunoassay for 1,25-dihydroxycholecalciferol. Clin Chem 26:5 (1980), 562–567.
Bouillon, R., Coopmans, W., Degroote, D.E., et al. Immunoradiometric assay of parathyrin with polyclonal and monoclonal region-specific antibodies. Clin Chem 36:2 (1990), 271–276.
Cavalier, E., Souberbielle, J.C., Gadisseur, R., et al. Inter-method variability in bone alkaline phosphatase measurement: clinical impact on the management of dialysis patients. Clin Biochem 47:13–14 (2014), 1227–1230.
Behets, G.J., Spasovski, G., Sterling, L.R., et al. Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism. Kidney Int 87:4 (2015), 846–856.
Dempster, D.W., Compston, J.E., Drezner, M.K., et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 28:1 (2013), 2–17.
Viaene, L., Behets, G.J., Heye, S., et al. Inflammation and the bone-vascular axis in end-stage renal disease. Osteoporos Int 27:2 (2016), 489–497.